Palatin Technologies (NYSEAMERICAN:PTN – Get Rating) had its price target lifted by equities research analysts at LADENBURG THALM/SH SH to $50.00 in a research report issued on Friday, September 9th, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reiterated a “buy” rating and set a $70.00 price objective on shares of Palatin Technologies in a research note on Thursday, September 8th.
Palatin Technologies Stock Performance
Shares of PTN traded up $0.37 during midday trading on Friday, hitting $8.33. 129,045 shares of the stock traded hands, compared to its average volume of 55,789. Palatin Technologies has a 1-year low of $4.00 and a 1-year high of $24.00. The company has a market cap of $77.20 million, a price-to-earnings ratio of -52.66 and a beta of 0.79.
Institutional Investors Weigh In On Palatin Technologies
Palatin Technologies Company Profile
Palatin Technologies, Inc, a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder.
- Get a free copy of the StockNews.com research report on Palatin Technologies (PTN)
- Still Lovin’ It: Investors Keep Visiting McDonald’s
- Did FedEx Just Deliver A Buying Opportunity?
- Autozone Shifts Back Into Rally-Mode, New Highs Are In Sight
- Upwork Shares Stumble into Bargain Territory
- Kroger’s is Your One-Stop Consumer Staples Stock
Receive News & Ratings for Palatin Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Palatin Technologies and related companies with MarketBeat.com's FREE daily email newsletter.